new
diseas
sever
acut
respiratori
distress
syndrom
sar
caus
sar
coronaviru
sarscov
emerg
begin
rapidli
spread
throughout
world
although
diseas
disappear
june
reemerg
exclud
develop
vaccin
sarscov
may
take
year
therefor
avail
effect
antivir
drug
sarscov
may
crucial
control
futur
sar
outbreak
review
experiment
clinic
data
potenti
antisar
drug
summaris
discuss
anim
model
studi
need
help
determin
intervent
warrant
control
clinic
test
sever
acut
respiratori
syndrom
sar
recent
recognis
sever
febril
lower
respiratori
ill
caus
see
front
matter
elsevi
bv
right
reserv
newli
identifi
coronaviru
sar
coronaviru
sarscov
ksiazek
et
al
peiri
et
al
sinc
first
report
outbreak
atyp
pneumonia
guandong
provinc
china
late
success
similar
outbreak
wide
report
march
onward
countri
territori
affect
patient
caus
least
death
berger
et
al
stadler
et
al
peiri
et
al
updat
inform
found
http
wwwwhointcsrsarsen
patient
may
progress
acut
respiratori
distress
syndrom
requir
mechan
ventilatori
support
overal
mortal
rate
mortal
vari
age
sar
affect
rel
children
gener
appear
milder
paediatr
age
group
contrast
mortal
rate
elderli
high
much
scientif
effort
focus
develop
vaccin
protect
futur
sar
outbreak
howev
chanc
rapidli
develop
effect
vaccin
difficult
judg
moment
anim
coronaviru
vaccin
report
exacerb
diseas
vaccin
anim
cavanagh
immunis
modifi
vaccinia
viru
ankarabas
recombin
vaccin
sar
associ
enhanc
hepat
ferret
weingartl
et
al
therefor
certain
precaut
consid
develop
sarscov
vaccin
due
potenti
detriment
effect
marshal
enserink
due
develop
effect
safe
vaccin
sarscov
could
take
year
moreov
clear
whether
diseas
reemerg
near
futur
unlik
futur
outbreak
reach
global
proport
taken
togeth
fact
limit
commerci
interest
sarscov
vaccin
may
prolong
vaccin
develop
therefor
search
effect
antivir
agent
sarscov
continu
order
prepar
well
possibl
futur
sar
outbreak
clinic
cours
sar
appear
follow
typic
pattern
peiri
et
al
initi
clinic
sign
fever
myalgia
system
symptom
gener
improv
day
initi
phase
viral
load
increas
higher
initi
viral
load
associ
wors
prognosi
chu
et
al
continu
viral
replic
associ
poor
clinic
outcom
chu
et
al
initi
viral
replic
phase
next
phase
sar
characteris
recurr
fever
hypoxaemia
radiolog
progress
pneumonia
although
viral
load
may
declin
peiri
et
al
show
progress
decreas
viral
shed
nasopharynx
stool
urin
day
day
onset
symptom
patient
follow
serial
rtpcr
measur
thu
immunemedi
lung
injuri
caus
overexuber
host
respons
may
contribut
clinic
worsen
second
phase
addit
higher
viral
load
lung
significantli
associ
shorter
durat
onset
ill
death
mazzulli
et
al
b
due
sudden
explos
emerg
diseas
empir
strategi
use
treat
patient
fujii
et
al
hui
wong
includ
variou
antibiot
antivir
agent
ribavirin
oseltamivir
proteas
inhibitor
corticosteroid
interferon
normal
human
immunoglobulin
prepar
neutralis
antibodi
fusion
inhibitor
silenc
sarscov
gene
rna
interfer
natur
product
glycyrrhizin
compon
liquoric
rout
repres
therapeut
possibl
sar
treatment
new
insight
field
sar
pathogenesi
sarscov
genom
structur
reveal
novel
potenti
therapeut
target
antivir
therapi
differ
anim
model
establish
enabl
examin
potenti
antisarscov
drug
vivo
articl
review
discuss
possibl
antivir
agent
may
effect
treatment
devast
infect
ribavirin
purin
nucleosid
analogu
discov
icn
pharmaceut
broad
spectrum
antivir
activ
sidwel
et
al
ribavirin
licens
countri
treatment
respiratori
syncyti
viru
rsv
infect
infant
combin
interferon
chronic
hepat
c
viru
infect
prevent
replic
larg
number
differ
rna
dna
virus
vitro
includ
myxo
paramyxo
arena
bunya
herp
adeno
pox
retrovirus
patient
lassa
fever
ribavirin
significantli
reduc
mortal
especi
therapi
initi
first
day
ill
mccormick
et
al
ribavirin
given
oral
absolut
bioavail
intraven
aerosol
differ
mechan
may
respons
antivir
effect
ribavirin
ribavirin
prevent
replic
virus
inhibit
enzym
inosin
monophosph
dehydrogenas
requir
synthesi
guanosin
triphosph
cameron
castro
leyssen
et
al
moreov
inhibit
viral
polymeras
activ
metabolit
ribavirin
inhibit
viral
cap
lethal
mutagenesi
rna
genom
may
contribut
antivir
effect
ribavirin
hong
cameron
vitro
inhibit
rsv
influenza
parainfluenza
virus
achiev
concentr
gml
anim
studi
show
ribavirin
effect
treatment
mous
coronaviru
hepat
sidwel
et
al
ning
et
al
although
ribavirin
littl
inhibitori
effect
coronaviru
replic
decreas
releas
proinflammatori
cytokin
eg
macrophag
mice
addit
ribavirin
switch
respons
respons
dendrit
cell
ribavirin
markedli
suppress
product
without
effect
dendrit
cell
matur
barn
et
al
rsvinfect
epitheli
cell
ribavirin
increas
virusinduc
ifnstimul
respons
element
isr
signal
therebi
enhanc
express
antivir
ifnstimul
respons
gene
isg
zhang
et
al
ribavirin
may
therefor
serv
immunomodul
irrespect
antivir
role
investig
initi
carri
laboratori
demonstr
ribavirin
inhibit
sarscov
replic
vero
african
green
monkey
kidney
cell
therapeut
achiev
concentr
cinatl
et
al
result
confirm
investig
use
subclon
vero
cell
stroher
et
al
chen
et
al
tan
et
al
howev
result
probabl
caus
insuffici
phosphoryl
ribavirin
activ
triphosphoryl
form
vero
cell
recent
studi
show
ribavirin
inhibit
sarscov
replic
foetal
rhesu
kidney
cell
concentr
gml
still
mean
plasma
level
treat
individu
rang
gml
iv
administr
mg
ribavirin
gml
oral
dose
mg
adult
koren
et
al
investig
effect
ribavirin
sarscov
replic
panel
sarscov
permiss
anim
human
cell
line
ribavirin
inhibit
sarscov
replic
strain
embryon
african
green
monkey
kidney
cell
pig
kidney
cell
line
human
colon
carcinoma
cell
line
primari
epitheli
human
kidney
cell
hpek
concentr
gml
find
suggest
multipl
cell
cultur
system
use
evalu
activ
antivir
agent
emerg
virus
sarscov
et
al
propos
treatment
protocol
sar
emphasi
combin
ribavirin
methylprednisolon
publish
report
clinic
effect
ribavirin
mostli
retrospect
case
seri
intrins
methodolog
problem
difficult
draw
firm
conclus
booth
et
al
dwosh
et
al
hsu
et
al
tsang
et
al
peiri
et
al
zhao
et
al
randomis
trial
conclud
ribavirin
efficaci
zhao
et
al
therefor
clinic
valu
ribavirin
treatment
sar
patient
regard
sceptic
especi
sinc
ribavirin
treatment
associ
sever
advers
effect
major
side
effect
ribavirin
anaemia
occur
sar
patient
booth
et
al
sung
et
al
anaemia
reduc
oxygen
transport
potenti
exist
problem
oxygen
tissu
hypoxia
signific
side
effect
includ
rais
transaminas
bradycardia
booth
et
al
well
hypocalcaemia
hypomagnesaemia
risk
teratogen
detail
studi
clinic
cours
viral
load
peiri
et
al
report
patient
given
standard
regimen
ribavirin
steroid
show
peak
viral
load
day
onset
ill
although
small
number
subject
includ
studi
indic
inabl
ribavirin
clear
sarscov
sar
patient
moreov
canadian
studi
found
sarscov
rna
multipl
lung
lobe
often
high
copi
number
time
death
ribavirin
treat
patient
mazzulli
et
al
earli
onset
hydrocortison
therapi
ribavirintr
patient
result
increas
plasma
sarscov
rna
concentr
second
third
week
ill
compar
receiv
placebo
instead
hydrocortison
enhanc
sarscov
mrna
hydrocortison
treat
patient
probabl
due
direct
effect
viru
replic
sinc
hydrocortison
influenc
sarscov
replic
cultur
cell
although
clinic
trial
support
use
ribavirin
sar
necessarili
mean
ribavirin
without
effect
viru
replic
treat
patient
possibl
antivir
effect
ribavirin
weak
improv
clinic
symptom
recent
publish
uncontrol
studi
report
ribavirin
reduc
viral
load
five
eight
patient
wang
et
al
moreov
studi
suggest
peak
inflammatori
cytokin
level
concur
peak
viral
load
preced
concur
maximum
pulmonari
infiltr
therefor
reduct
viral
load
earli
phase
sar
may
reduc
activ
proinflammatori
cytokin
subsequ
result
milder
cours
diseas
clinic
find
togeth
observ
antivir
activ
ribavirin
differ
sarscovinfect
cell
line
show
ribavirin
critic
investig
sar
anim
model
allow
detail
apprais
activ
ribavirin
may
use
combin
antivir
drug
interferon
proteas
inhibitor
see
addit
ribavirin
analogu
previous
develop
treatment
hcv
viral
diseas
potenti
drug
treatment
sar
sever
ribavirin
analogu
stronger
antivir
activ
compar
ribavirin
de
clercq
et
al
potent
conger
group
eicar
show
antivir
potenc
differ
rna
virus
greater
ribavirin
analogu
viramidin
levovirin
specif
develop
treatment
patient
hepat
c
foster
recent
viramidin
livertarget
prodrug
ribavirin
present
suggest
organ
target
ribavirin
may
reason
therapeut
approach
lin
et
al
wu
et
al
viramidin
activ
deamin
liver
enzym
adenosin
deaminas
experiment
clinic
data
show
improv
viramidin
distribut
liver
red
blood
cell
compar
ribavirin
lin
et
al
b
develop
ribavrin
analogu
target
organ
lung
intestin
may
relev
treatment
sar
levovirin
ie
lisom
ribavirin
associ
lesser
degre
haemolyt
anaemia
appear
safe
anim
studi
well
toler
phase
studi
healthi
volunt
hugl
cerni
lin
et
al
contrast
ribavirin
levovirin
direct
antivir
activ
retain
immunomodulatori
activ
ribavirin
viru
infect
permiss
cell
prompt
innat
immun
system
establish
first
line
defenc
interferon
ifn
play
key
role
event
sinc
activ
innat
immun
system
help
shape
immun
ifn
consist
multipl
type
speci
ifn
ifn
one
type
ii
speci
antivir
activ
sen
katz
et
al
urosev
type
ifn
function
structur
similar
ifn
induc
sever
parallel
antivir
pathway
cell
includ
four
major
factor
oligoadenyl
synthetas
oa
protein
familyribonucleas
l
rnase
l
dsrnadepend
protein
kinas
pkr
mx
protein
adenosin
deaminas
rnaspecif
adar
sen
these
pathway
specif
particular
group
virus
although
one
pathway
may
control
infect
singl
viru
common
featur
among
antivir
pathway
exclud
mx
protein
requir
dsrna
common
activ
substrat
ifninduc
protein
factor
oa
pkr
enzym
requir
nonspecif
associ
dsrna
activ
antivir
effect
use
dsrna
substrat
deamin
adenosin
convers
inosin
exist
consider
residu
effect
type
ifn
encephalomyocard
viru
emcv
mice
lack
function
rnase
l
pkr
mx
suggest
presenc
addit
pathway
zhou
et
al
sensit
coronavirus
includ
avian
infecti
bronchiti
viru
murin
hepat
viru
mhv
transmiss
gastroenter
viru
tgev
human
coronavirus
ifn
demonstr
vitro
vivo
sperber
hayden
pei
et
al
minigawa
et
al
lucchiari
et
al
weingartl
derbshir
although
type
ifn
effect
coronaviru
infect
studi
suggest
type
ifn
may
potent
one
studi
even
stimul
product
infecti
virion
human
coronaviru
strain
human
neuron
cell
collin
potent
mhv
compar
mous
model
combin
treatment
interferon
show
synergist
antivir
effect
fuchizaki
et
al
clinic
experi
ifn
treatment
coronaviru
infect
experiment
set
healthi
volunt
treat
intranas
recombin
ifn
iuday
placebo
day
expos
coronaviru
direct
intranas
inocul
eighth
day
treatment
turner
et
al
therapi
ifn
shorten
durat
reduc
sever
coronaviru
cold
symptom
suggest
intranas
may
effect
prophylact
treatment
coronaviru
infect
human
similarli
intranas
ifn
spray
given
day
day
viru
challeng
protect
human
volunt
infect
coronaviru
tyrel
numer
vitro
studi
effect
ifn
sarscov
replic
observ
cinatl
et
al
first
publish
vitro
studi
compar
effect
differ
class
ifn
sarscov
replic
demonstr
effect
inhibit
sarscov
replic
cinatl
et
al
effect
recombin
intron
essex
pharma
munich
germani
betaferon
schere
berlin
germani
imukin
boehring
ingelheim
ingelheim
germani
two
differ
viru
strain
compar
two
differ
cell
line
african
green
monkey
kidney
cell
line
vero
human
colorect
adenocarcinoma
cell
line
pretreat
ec
concentr
compound
need
inhibit
cytopath
effect
control
valu
sarscov
vero
cell
lower
respect
similar
result
obtain
comparison
antisarscov
effect
use
sarscov
strain
vero
cell
strain
cell
contrast
inhibit
sarscov
replic
ad
viru
infect
ifn
show
antisarscov
activ
although
shown
inhibit
sarscov
replic
effect
compar
experi
cinatl
et
al
sever
laboratori
report
differ
subtyp
human
leukocyt
highli
effect
sarscov
replic
chen
et
al
b
hensley
et
al
sainz
et
al
spiegel
et
al
stroher
et
al
tan
et
al
zheng
et
al
contrast
initi
studi
cinatl
et
al
investig
exclus
perform
monkey
kidney
cell
line
includ
vero
cell
permiss
human
intestin
epitheli
cell
line
infect
differ
sarscov
strain
analysi
cellular
gene
express
highdens
oligonucleotid
array
reveal
upregul
numer
ifninduc
gene
includ
mxa
cinatl
et
al
progress
viru
replic
despit
express
gene
suggest
play
signific
role
control
sarscov
replic
vitro
fact
sarscov
replic
observ
vero
cell
stabli
express
mxa
spiegel
et
al
result
suggest
ifninduc
protein
must
respons
inhibitori
effect
type
iifn
sarscov
replic
moreov
sarscov
develop
abil
evad
ifn
system
inhibit
induct
endogen
prevent
activ
transcript
factor
interferon
regulatori
factor
essenti
promot
activ
spiegel
et
al
although
shown
littl
antivir
effect
sarscov
replic
vitro
cinatl
et
al
tan
et
al
b
spiegel
et
al
zheng
et
al
two
recent
observ
suggest
simultan
incub
vero
cell
may
act
synergist
sarscov
infect
sainz
et
al
scagnolari
et
al
activ
type
ifn
sarscov
confirm
anim
studi
treatment
cynomolg
macaqu
pegyl
recombin
pegintron
prior
sarscovinfect
substanti
protect
type
pneumocyt
main
target
cell
sarscov
infect
macaqu
sarscov
infect
vivo
use
pegyl
day
postexposur
protect
type
pneumocyt
less
effect
although
vitro
data
suggest
direct
influenc
pegyl
sarscov
replic
author
determin
vivo
protect
pegyl
caus
direct
antivir
activ
immunomodulatori
effect
taken
togeth
experiment
data
strongli
encourag
test
type
ifn
treatment
sar
limit
experi
ifn
treatment
sar
patient
result
two
clinic
studi
first
studi
describ
treatment
sarspati
guangzhou
capit
guangdong
zhao
et
al
author
conclud
best
outcom
achiev
combin
highdos
steroid
quinolon
plu
azithromycin
author
opinion
use
result
obviou
benefici
effect
second
studi
ifn
infergen
intermun
brisban
california
usa
nonnatur
occur
synthet
recombin
type
contain
amino
acid
posit
commonli
observ
amino
acid
nonallel
subtyp
use
loutfi
et
al
thirteen
patient
receiv
singl
treatment
corticosteroid
compar
nine
patient
addit
receiv
ifn
loutfi
et
al
use
ifn
result
rapid
resolut
radiograph
lung
abnorm
better
oxygen
satur
level
moreov
ifn
patient
show
less
increas
creatin
kinas
level
rapid
return
lactat
dehydrogenas
normal
level
elev
lactat
dehydrogenas
creatin
kinas
level
assum
indic
lung
parenchym
damag
associ
poor
prognosi
loutfi
et
al
addit
treatment
ifn
decreas
median
durat
peak
lung
involv
ifn
treat
patient
need
supplement
oxygen
shorter
period
howev
latestag
diseas
four
six
critic
ill
patient
cohort
die
despit
combin
therapi
rais
possibl
earli
treatment
import
experi
drug
treatment
first
sar
outbreak
led
nation
institut
allergi
infecti
diseas
sponsor
collabor
antivir
studi
group
develop
placebocontrol
clinic
treatment
protocol
patient
earli
sar
levi
et
al
one
possibl
strategi
improv
direct
antivir
effect
ifn
may
combin
antivir
combin
ribavirin
result
synergist
increas
sarscov
replic
inhibit
differ
human
cell
line
similar
result
found
chen
et
al
contrast
tan
et
al
find
synergist
effect
type
interferon
ribavirin
test
combin
ribavirin
interferon
anim
model
sar
necessari
judg
vivo
activ
contrast
sarscov
proteas
cystein
proteas
fan
et
al
proteas
belong
aspartyl
proteas
todd
et
al
develop
proteas
inhibitor
base
knowledg
gagpol
polypeptid
precursor
cleavag
site
recognis
enzym
approach
led
develop
highli
potent
select
inhibitor
antisarscov
activ
proteas
inhibitor
identifi
screen
compound
includ
antivir
drug
alreadi
human
clinic
use
howev
result
inconsist
across
laboratori
anim
model
data
publish
document
vivo
antivir
activ
sarscov
first
vitro
data
present
yuen
prevent
cure
sar
seminar
held
guangzhou
septemb
confer
yuen
mention
found
suppress
effect
lopinavir
ritonavir
sarscov
replic
antivir
effect
observ
singl
drug
synergist
increas
use
combin
hong
kong
group
report
later
antivir
activ
lopinavir
concentr
gml
chu
et
al
close
peak
gml
trough
gml
lopinavir
plasma
level
treat
patient
hurst
fauld
yamamoto
et
al
demonstr
nelfinavir
inhibit
replic
sarscov
vero
cell
nanomolar
concentr
easili
achiev
plasma
treat
patient
contrast
studi
fail
demonstr
antivir
activ
proteas
inhibitor
includ
ritonavir
lopinavir
concentr
similarli
tan
et
al
observ
antisarscov
activ
indinavir
nelfinavir
saquinavir
therapeut
achiev
concentr
first
clinic
result
treatment
sar
patient
proteas
inhibitor
report
research
group
hong
kong
studi
patient
sar
treat
formul
lopinavir
lowdos
ritonavir
kaletra
abbott
addit
standard
treatment
protocol
includ
antibiot
ribavirin
corticosteroid
adopt
hospit
author
patient
match
control
subject
retriev
hospit
author
sar
central
databas
match
done
respect
age
sex
presenc
comorbid
lactat
dehydrogenas
level
use
steroid
therapi
patient
treat
lopinavirritonavir
divid
two
subgroup
analysi
receiv
lopinavirritonavir
initi
treatment
patient
receiv
lopinavirritonavir
salvag
therapi
patient
group
compar
match
cohort
patient
respect
hong
kong
research
group
found
use
lopinavirritonavir
initi
treatment
associ
lower
overal
mortal
rate
intub
rate
compar
match
cohort
subject
receiv
lopinavirritonavir
respect
p
howev
subgroup
patient
receiv
lopinavirritonavir
salvag
therapi
show
differ
overal
mortal
rate
rate
oxygen
desatur
intub
compar
match
cohort
suggest
earli
use
liponavirritonavir
effect
treatment
sar
benefici
effect
earli
use
liponavirritonavir
includ
reduct
corticosteroid
use
fewer
nosocomi
infect
decreas
viral
load
rise
peripher
lymphocyt
count
chu
et
al
possibl
clinic
util
proteas
inhibitor
also
suggest
observ
perform
patient
hospitalis
guangzhou
chen
cao
patient
hospitalis
guangzhou
report
none
patient
hospitalis
togeth
patient
sar
hospit
floor
becam
infect
sarscov
patient
receiv
haart
hospitalis
hand
member
medic
staff
directli
serv
floor
contract
sar
howev
find
interpret
care
sinc
exposur
risk
clearli
higher
medic
staff
patient
floor
although
improv
clinic
outcom
patient
receiv
liponavirritonavir
part
initi
therapi
may
due
fact
serum
concentr
could
inhibit
viru
data
anim
experi
exist
possibl
mechan
remain
obscur
proteas
inhibitor
may
bind
activ
site
sarscov
main
proteinas
zhang
yap
howev
least
case
nelfinavir
inhibit
main
sarscov
proteinas
major
mechan
sarscov
inhibit
yamamoto
et
al
proteas
inhibitor
also
influenc
cellular
enzym
involv
apoptosi
ghibelli
et
al
antigen
process
present
andr
et
al
block
proinflammatori
cytokin
product
inhibit
cellular
transcript
factor
nfb
piccinini
et
al
equil
et
al
therefor
possibl
addit
viral
target
cellular
protein
may
influenc
proteas
inhibitor
may
contribut
clinic
antisar
activ
also
note
sar
patient
treat
lopinavirritonavir
also
receiv
ribavirin
initi
antivir
therapi
chu
et
al
therefor
possibl
combin
ribavirin
proteas
inhibitor
led
synergist
antivir
effect
demonstr
experi
sarscovinfect
cultur
cell
chu
et
al
nitric
oxid
import
signal
molecul
cell
involv
wide
rang
biolog
process
rang
vasodilat
bloodpressur
control
neurotransmiss
also
involv
nonspecif
innat
host
defenc
particip
complex
mechan
tissu
injuri
act
major
mediat
inflammatori
process
apoptosi
ignarro
play
key
part
host
defenc
bacteria
protozoa
tumour
cell
antivir
activ
describ
differ
virus
includ
dna
virus
murin
poxviru
herp
simplex
viru
epsteinbarr
viru
rna
virus
polioviru
coxsackieviru
japanes
enceph
viru
murin
coronaviru
lane
et
al
pope
et
al
reiss
komatsu
torr
et
al
donor
hydroxynitrosihydrazino
bisethamin
deta
nonoat
earli
found
inhibit
sarscov
vero
cell
cinatl
et
al
addit
deta
nonoat
inhibit
sarscov
replic
intestin
cell
line
nontox
concentr
dose
depend
manner
recent
two
vitro
studi
demonstr
inhibitori
effect
sarscov
replic
vero
cell
keyaert
et
al
test
two
donor
compound
includ
snitrosonacetylpenicillamin
snap
sodium
nitroprussid
snp
antivir
activ
estim
inhibit
sarscov
cytopath
effect
surviv
rate
sarscovinfect
cell
greatli
increas
treatment
snap
snp
akerstrom
et
al
report
snap
inhibit
replic
cycl
sarscov
dosedepend
manner
treatment
snap
result
reduct
yield
progeni
viru
also
demonstr
antisarscov
activ
may
least
part
due
stimulatori
effect
induc
nitric
oxid
synthas
ino
express
demonstr
experi
use
ino
inhibitor
akerstrom
et
al
although
antivir
mechan
elucid
seem
inhibit
earli
stage
sarscov
replic
akerstrom
et
al
rescu
clinic
trial
beij
suggest
inhal
may
benefit
sar
patient
six
patient
inhal
improv
arteri
oxygen
enabl
reduct
inspir
oxygen
therapi
airway
pressur
support
chest
radiographi
show
decreas
spread
densiti
lung
infiltr
moreov
posit
effect
remain
termin
inhal
possibl
addit
vasododilatori
effect
inhal
exert
antivir
activ
hand
harm
role
mani
system
includ
develop
inflammatori
lung
diseas
note
seem
play
part
develop
pneumonia
caus
influenza
viru
herp
simplex
viru
type
anim
model
akaik
et
al
adler
et
al
howev
peak
human
experiment
infect
influenza
viru
late
associ
clinic
symptom
murphi
et
al
suggest
contrast
mous
model
may
exert
antivir
activ
without
harm
effect
human
howev
similar
studi
report
natur
influenza
influenza
viral
pneumonia
human
calpain
abund
intracellular
calciumdepend
cystein
proteas
mammalian
tissu
perrin
huttenloch
enzymat
activ
calpain
regul
intracellular
calcium
ion
specif
endogen
calpain
inhibitor
calpastatin
perrin
huttenloch
wang
suggest
like
proteasom
calpain
part
regulatori
proteolyt
system
calpain
play
physiolog
regulatori
role
membran
cytoskelet
remodel
includ
mitosi
apoptosi
regul
neumar
et
al
sever
studi
suggest
calpain
may
involv
regul
viru
replic
virusinduc
cytopath
effect
monocytesmacrophag
calpain
mediat
activ
induc
calcium
signal
moreov
calpain
inhibitor
shown
inhibit
activ
latent
infect
cell
teranishi
et
al
reovirusinduc
apoptosi
preced
increas
cellular
calpain
activ
block
calpain
inhibitor
debiasi
et
al
debiasi
et
al
mous
model
reovirusinduc
myocard
specif
calpain
inhibitor
slightli
inhibit
viru
replic
protect
mice
myocardi
injuri
debiasi
et
al
barnard
et
al
demonstr
two
calpain
inhibitor
includ
valleucho
calpain
inhibitor
vi
zvalphealacho
calpain
inhibitor
iii
potent
inhibitor
sarscov
replic
viru
yield
reduct
assay
calpain
inhibitor
vi
effect
concentr
ec
calpain
inhibitor
iii
ec
interestingli
observ
sarscov
abl
induc
calpain
activ
infect
vero
cell
unpublish
result
conceiv
addit
antivir
effect
calpain
inhibitor
also
prevent
cellular
lysi
inhibit
apoptosi
may
induc
sarscov
infect
cell
yan
et
al
tan
et
al
interestingli
proteas
ritonavir
indinavir
abl
inhibit
calpaininduc
apoptosi
wan
depetrillo
ghibelli
et
al
therefor
possibl
proteas
inhibitor
protect
infect
cell
sarscov
induc
lysi
calpain
inhibit
chu
et
al
yamamoto
et
al
numer
calpain
inhibitor
recent
develop
treatment
differ
pathophysiolog
condit
cataract
spinal
cord
injuri
multipl
organ
failur
await
clinic
trial
cuzzocrea
et
al
ray
et
al
biswa
et
al
investig
role
calpain
sarscov
infect
anim
model
warrant
triterpen
glycosid
glycyrrhiz
acid
glycyrrhizin
gl
aglycon
acid
gla
intens
investig
bioactiv
compound
licoric
root
glycyrrhiza
radix
baltina
compound
report
antitumour
antiinflammatori
antivir
properti
shibata
gl
activ
broad
spectrum
virus
includ
herp
virus
pompei
et
al
lin
lampi
et
al
flavivirus
cranc
et
al
human
immunodefici
viru
gl
one
first
compound
found
activ
sarscov
vitro
cinatl
et
al
gl
inhibit
sarscov
replic
ec
vero
cell
chen
et
al
confirm
result
use
cell
line
ec
howev
found
gl
ineffect
cell
disregard
differ
differ
cell
line
ec
suggest
antivir
activ
concentr
difficult
achiev
administr
patient
mechan
glycyrrhizin
activ
sarscov
unclear
gl
affect
mani
cellular
signal
pathway
protein
kinas
c
obrian
et
al
casein
kinas
ii
harada
et
al
transcript
factor
cfo
crel
nuclear
factor
b
cherng
et
al
gl
also
shown
activ
rasrafmapk
pathway
increas
intracellular
camp
level
camprespons
element
bind
creb
phosphoryl
furthermor
gl
may
influenc
viru
replic
upregul
express
induc
nitric
oxid
synthas
product
nitric
oxid
yi
et
al
exert
antivir
activ
sarscov
see
prepar
gl
combin
lcystein
glycin
stronger
neominophagen
c
snmc
regist
japan
countri
snmc
administ
intraven
use
appar
success
treatment
chronic
viral
hepat
miyak
et
al
upper
respiratori
tract
infect
yanagawa
et
al
haiy
et
al
report
annual
meet
societi
infecti
parasit
diseas
chines
medic
associ
use
intraven
snmc
treatment
sar
patient
compar
patient
sole
treat
corticosteroid
snmc
dose
rang
use
treatment
hepat
c
intraven
administr
glycyrrhizin
serum
level
glycyrrhizin
rang
gml
van
rossum
et
al
treatment
snmc
reduc
maxim
use
corticosteroid
dose
durat
admiss
howev
antivir
effect
assess
apart
antivir
activ
gl
exert
divers
immunomodulatori
activ
may
protect
virusinfect
animalshuman
baltina
gl
reduc
mortal
morbid
mice
infect
lethal
dose
influenza
viru
although
inhibit
influenza
viru
replic
utsunomiya
et
al
therefor
conclud
benefici
effect
sar
patient
may
result
antivir
andor
pharmacolog
activ
immunomodul
recent
report
gl
shown
inhibit
accumul
platelet
lung
mice
respons
lipopolysaccharid
lp
therebi
inhibit
lpsinduc
mortal
yu
et
al
result
suggest
gl
consid
drug
treatment
acut
respiratori
distress
syndrom
support
idea
gl
may
use
drug
sar
due
benefici
effect
sarsassoci
lung
patholog
wu
et
al
screen
commerciali
avail
small
molecul
antisarscov
activ
two
substanc
activ
sarscov
concentr
shown
share
similar
gl
use
intern
speci
inform
system
isi
databas
elong
gl
carbohydr
chain
introduct
amino
acid
heterocycl
fragment
significantli
affect
bioactiv
glycosid
baltina
therefor
test
antisarscov
activ
sever
glderiv
find
potent
compound
hoever
et
al
gla
inhibit
sarscov
replic
demonstr
sugar
moieti
essenti
antisarscov
effect
introduct
nacetylgycosamin
glycosid
chain
gl
increas
antisarscov
activ
compar
gl
result
ic
hoever
et
al
find
show
chemic
modif
may
lead
gl
deriv
increas
antisarscov
activ
cleavag
process
sarscov
polyprotein
special
proteinas
socal
sarscov
proteinas
cov
mpro
key
step
replic
sarscov
make
attract
target
develop
novel
drug
sar
fan
et
al
homolog
model
perform
variou
group
xiong
et
al
conform
flexibl
substrat
bind
site
studi
specif
cyctein
proteas
overal
backbon
fold
similar
trypsinelik
serin
proteas
respons
primarili
catalyt
cleavag
glutamineglycin
serin
peptid
bond
screen
current
avail
drug
chemic
librari
led
identif
novel
inhibitor
identif
current
avail
drug
provid
advantag
use
immedi
treatment
sar
patient
bind
pocket
affin
predict
clinic
use
antihiv
lopinavir
ritonavir
antipsychot
promazin
antiparasit
drug
niclosamid
zhang
yap
discuss
hiv
proteas
inhibitor
may
provid
effect
treatment
patient
sar
niclosamid
antihelminth
drug
total
abolish
sarscov
antigen
product
vero
cell
concentr
ie
least
cytotox
concentr
wu
et
al
screen
agent
led
identif
peptid
agent
target
wu
et
al
agent
design
transit
state
analogu
inhibitor
hiv
proteas
inhibit
ki
model
studi
indic
compound
bind
specif
activ
site
sar
proteas
cmk
anoth
peptid
inhibitor
bind
irrevers
enzym
activ
site
wherea
bifunct
aryl
boron
acid
compound
revers
inhibit
appear
target
cluster
serin
residu
close
enzym
site
bacha
et
al
jain
et
al
develop
sever
electrophil
ketoglutamin
analogu
phthalhydrazido
group
revers
inhibitor
sar
liu
et
al
found
sever
noncoval
inhibitor
sar
use
virtual
screen
molecular
dock
chemic
databas
one
potent
inhibitor
calmidazolium
well
known
antagonist
calmodulin
antivir
activ
compound
sarscov
vitro
vivo
remain
elucid
entri
process
envelop
virus
includ
coronavirus
usual
involv
three
step
includ
attach
receptor
bind
viruscel
fusion
mediat
viral
envelop
protein
gallagh
buchmeier
spike
protein
sarscov
type
membranebound
protein
essenti
viral
attach
host
cell
receptor
cell
fusion
precursor
pro
divid
subunit
interact
subunit
angiotensinconvert
enzym
function
receptor
sarscov
requir
receptor
bind
permiss
cell
transmembran
subunit
play
crucial
role
viruscel
fusion
process
kliger
levanon
spiga
et
al
human
monoclon
antibodi
protein
see
block
associ
sarscov
indic
site
could
target
drug
develop
sui
et
al
ethylamino
acid
first
smallmolecularweight
inhibitor
found
interact
activ
catalyt
site
towler
et
al
whether
inhibit
sarscov
infect
remain
elucid
huentelman
et
al
screen
approxim
small
molecul
silico
molecular
dock
approach
approach
identifi
n
aziridineethamin
naae
novel
inhibitor
also
effect
block
sarscov
spike
proteinmedi
cell
fusion
develop
inhibitor
antivir
drug
may
limit
fact
sarscov
use
differ
altern
cellular
receptor
exampl
addit
cellular
glycoprotein
also
call
lsign
dcsignr
identifi
receptor
sarscov
jeffer
et
al
sarscov
sprotein
pseudotyp
viru
vector
prepar
function
studi
sarscov
cellular
tropism
entri
permiss
cell
girogl
et
al
yi
et
al
yi
et
al
use
hivlucsarscov
pseudotyp
viru
twostep
screen
method
consist
frontal
affin
chromatographymass
spectrometri
coupl
viral
infect
assay
identifc
sarscov
entri
inhibitor
chines
herbal
medicinebas
approach
identifi
two
small
molecul
tgg
luteolin
potent
sarscov
inhibitor
tgg
exhibit
promin
antisarscov
activ
ic
select
index
luteolin
exert
select
index
quercetin
structur
relat
luteolin
show
also
inhibitori
activ
cellular
entri
sarscov
quercetin
approv
ingredi
antioxid
antiallerg
medicin
mani
countri
thu
offer
great
promis
potenti
drug
clinic
treatment
sar
sinc
tgg
luteolin
identifi
analysi
bind
protein
sarscov
small
molecul
like
work
abil
block
viru
entri
interf
fusion
process
yi
et
al
import
target
antivir
drug
interfer
fusion
process
heptad
repeat
region
hr
locat
protein
bosch
et
al
least
two
hr
common
featur
type
membran
glycoprotein
envelop
virus
coronaviru
sprotein
influenzaviru
hemaglutinin
env
paramyxoviru
f
protein
lescar
et
al
viru
bind
receptor
proton
endocytosi
class
fusion
protein
proceed
seri
conform
chang
mediat
membran
fusion
host
cell
peptid
deriv
protein
shown
inhibit
sarscov
infect
albeit
much
higher
concentr
similar
inhibitor
need
prevent
hiv
entri
bosch
et
al
liu
et
al
mani
nucleosid
analogu
test
aim
inhibit
sarscov
rna
polymeras
howev
hydroxycytidin
show
activ
sarscov
replic
cell
cultur
low
level
ec
select
index
barnard
et
al
two
nucleosid
analogu
pyrazofurin
inhibitor
orotidin
monophosph
decarboxylas
inhibit
replic
sarscov
vero
cell
nontox
dose
select
indic
respect
cinatl
et
al
although
drug
probabl
toxic
treatment
sar
patient
may
repres
lead
compound
develop
potent
antisarscov
agent
addit
substanc
discuss
eg
glycyrrhizin
luteolin
tgg
numer
small
molecul
herbal
origin
shown
activ
sarscov
especi
compon
tradit
chines
medicin
tcm
found
effect
inhibitor
sarscov
replic
vitro
may
explain
benefici
effect
tcm
observ
patient
sar
zhang
et
al
liu
et
al
exampl
baicalin
flavonoid
deriv
scutellaria
baicalensi
inhibit
sarscov
replic
vero
cell
concentr
may
achiev
vivo
intraven
administr
herbal
constitu
one
pharmacolog
activ
compon
tcm
herb
panax
ginseng
aescin
major
activ
principl
hors
chestnut
tree
reserpin
natur
occur
alkaloid
produc
sever
member
genu
rauwolfia
inhibit
sarscov
replic
nontox
concentr
wu
et
al
inhibitori
effect
sarscov
replic
rel
high
select
indic
report
differ
substanc
geldanamycin
ligand
heat
shock
protein
inhibit
sarscov
replic
select
index
ec
geldanamycin
product
hygroscopicu
interfer
cellular
chaperon
seem
major
mechan
cytotox
antivir
action
workman
li
et
al
geldanamycin
analogu
develop
treatment
malign
diseas
well
toler
patient
clinic
trial
workman
chloroquin
show
antisarscov
activ
vero
cell
select
index
ec
ec
chloroquin
cell
cultur
concentr
chloroquin
reach
human
plasma
follow
treatment
acut
malaria
dose
mgkg
day
charmot
coulaud
promis
antisarscov
agent
includ
aglycon
deriv
antibiot
vancomycin
eremomycin
teicoplanin
balzarini
et
al
mannosespecif
plant
lectin
deriv
galanthu
nivali
snowdrop
hippeastrum
hybrid
amarylli
balzarini
et
al
allium
porrum
leek
aurintricarboxyl
acid
inhibit
sarscov
replic
vero
cell
select
index
ec
gml
low
toxic
vitro
vivo
justifi
investig
show
whether
substanc
may
potenti
antisarscov
medicin
de
clercq
short
interf
rna
sirna
inhibit
express
specif
viral
gene
also
seem
effect
decreas
sarscov
replic
cell
line
zhang
et
al
zhang
et
al
et
al
wang
et
al
wu
et
al
recent
observ
mous
model
demonstr
diseas
airway
caus
influenza
viru
respiratori
syncyti
viru
andor
parainfluenza
viru
infect
specif
prevent
sirna
instil
intranas
without
transfect
reagent
ge
et
al
tompkin
et
al
bitko
et
al
zhang
et
al
find
suggest
properli
design
low
dosag
inhal
sirna
might
offer
specif
fast
potent
easili
applic
antivir
regimen
respiratori
viral
diseas
human
differ
group
hong
kong
local
use
plasma
donat
patient
recov
sar
soo
et
al
wong
et
al
administ
sar
patient
human
convalesc
plasma
appar
benefici
effect
use
rel
earli
cours
ill
cheng
et
al
similar
therapeut
sar
studi
observ
suffer
lack
randomis
control
problem
address
prepar
futur
outbreak
sar
novel
infecti
diseas
muller
et
al
nevertheless
base
preliminari
posit
find
suggest
sar
hyperimmun
globulin
contain
high
titr
sarscovneutralis
antibodi
produc
store
use
possibl
futur
outbreak
burnouf
radosevich
ali
rational
behind
suggest
strengthen
prophylact
antibodi
use
mice
sever
group
produc
characteris
monoclon
sarscovneutralis
antibodi
aim
find
immunoprophylact
agent
immedi
protect
possibl
therapeut
efficaci
traggiai
et
al
analys
memori
repertoir
patient
recov
sar
patient
b
cell
transform
differ
antibodi
isol
neutralis
sarscov
concentr
rang
recognis
differ
antigen
addit
one
antibodi
bind
sarscov
sprotein
inhibit
sarscov
infect
mice
appli
prior
infect
antibodi
describ
sui
et
al
neutralis
sarscov
vitro
bind
domain
sarscov
spike
protein
compet
solubl
sarscov
receptor
author
therefor
conclud
human
monoclon
antibodi
may
clinic
use
viral
entri
inhibitor
greenough
et
al
demonstr
protect
efficaci
two
monoclon
antibodi
appli
prophylact
mice
plan
conduct
clinic
trial
use
mab
human
monoclon
antibodi
direct
epitop
within
receptorbind
region
use
antibodi
phage
display
technolog
screen
larg
naiv
antibodi
librari
reactiv
whole
inactiv
sarscov
van
den
brink
et
al
select
eight
human
monoclon
antibodi
three
direct
epitop
locat
within
minim
receptorbind
region
sprotein
abl
neutralis
sarscov
vitro
antibodi
highest
potenc
assess
prophylact
efficaci
vivo
use
ferret
model
sarscov
infect
ter
meulen
et
al
dose
mgkg
inject
intraperiton
significantli
reduc
sarscov
replic
anim
lung
prevent
develop
macroscop
visibl
sarscov
lung
lesion
viral
shed
pharynx
thu
human
monoclon
sarscovneutralis
antibodi
may
potenti
use
prevent
infect
individu
expos
sarscov
might
also
use
earli
treatment
sar
patient
reduc
sever
ill
likelihood
sarscov
transmiss
other
howev
doserespons
safeti
studi
still
need
conduct
moreov
studi
address
efficaci
safeti
administ
neutralis
antibodi
patient
establish
infect
outstand
foxwel
cripp
substanti
function
chang
detect
spike
glycoprotein
sarscov
isol
obtain
sar
case
late
guangdong
provinc
two
palm
civet
depend
less
receptor
markedli
resist
antibodi
inhibit
human
antibodi
neutralis
pseudotyp
lentivirus
express
glycoprotein
deriv
human
sarscov
isol
enhanc
entri
two
pseudovirus
deriv
civet
viru
glycoprotein
mechan
enhanc
involv
interact
antibodi
conform
epitop
bind
domain
data
show
entri
sarscov
enhanc
antibodi
underscor
need
address
evolv
divers
newli
emerg
viru
immun
therapi
born
mind
case
respiratori
syncyti
viru
infect
clinic
avail
humanis
monoclon
antibodi
palivizumab
prophylact
efficaci
disappoint
treatment
establish
infect
rodriguez
et
al
numer
substanc
identifi
promis
antisarscov
agent
vitroexperi
howev
data
antisarscov
activ
strongli
differ
differ
laboratori
therefor
agent
found
inhibit
sarscov
replic
differ
independ
laboratori
preferenti
consid
clinic
trial
type
interferon
consist
found
inhibit
sarscov
replic
vitro
mani
independ
research
cinatl
et
al
hensley
et
al
spiegel
et
al
tan
et
al
b
chen
et
al
sainz
et
al
scagnolari
et
al
dahl
et
al
agent
evalu
predict
anim
model
establish
anim
model
includ
cynomolg
macaqu
kuiken
et
al
row
et
al
ferret
martina
et
al
domest
cat
martina
et
al
mice
balbc
african
green
monkey
golden
syrian
hamster
robert
et
al
anim
model
alreadi
use
demonstr
antivir
activ
therapeut
antibodi
ter
meulen
et
al
traggiai
et
al
cynomolg
macaqu
ferret
develop
lung
patholog
kuiken
et
al
row
et
al
martina
et
al
wherea
clinic
diseas
detect
african
green
monkey
domest
cat
martina
et
al
bukreyev
et
al
small
anim
model
special
interest
evalu
antivir
drug
sarscovinfect
golden
syrian
hamster
repres
auspici
small
anim
model
sar
contrast
mous
model
sarscov
replic
higher
titr
longer
durat
respiratori
tract
hamster
accompani
signific
patholog
moreov
viraemia
extrapulmonari
spread
sarscov
liver
spleen
seen
hamster
mice
current
antivir
therapi
proven
valu
sarscov
diseas
number
potenti
antisar
agent
identifi
inconsist
result
differ
group
investig
compound
show
need
standardis
vitro
suscept
test
method
determin
correl
vitro
vivo
antivir
activ
therefor
one
import
field
search
sar
antivir
therapi
valid
predict
correl
vitro
activ
antivir
effect
relev
anim
model
reflect
situat
sarscovinfect
human
possibl
futur
sar
outbreak
clinic
protocol
need
rapidli
assess
clinic
valu
antivir
therefor
scientist
involv
sar
research
cooper
identifi
promis
antivir
strategi
clinic
evalu
ration
effort
offer
sar
patient
best
avail
treatment
